KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

ClearPoint Neuro (CLPT) Accumulated Depreciation & Amortization (2011 - 2025)

ClearPoint Neuro recorded quarterly Accumulated Depreciation & Amortization of $1.7 million in Q4 2025, up 758.5% quarter-over-quarter from $200000.0 in Q4 2024, and up 758.5% year-over-year from $200000.0 in Q4 2024.

ClearPoint Neuro's Accumulated Depreciation & Amortization history runs 15 years deep, the most recent figure standing at $1.7 million for Q4 2025.

  • In Q4 2025, Accumulated Depreciation & Amortization rose 758.5% year-over-year to $1.7 million; the TTM figure through Dec 2025 stood at $1.7 million (up 758.5% YoY), while the FY2025 annual figure was $1.7 million, up 758.5% from the prior year.
  • Accumulated Depreciation & Amortization came in at $1.7 million for Q4 2025 at ClearPoint Neuro, up from $200000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.7 million in Q4 2025 to a low of $159000.0 in Q4 2021.
  • A 5-year average of $504000.0 and a median of $200000.0 in 2023 frame the typical range for Accumulated Depreciation & Amortization.
  • Across the five-year window, Accumulated Depreciation & Amortization slumped 52.4% in 2021 and surged 758.5% in 2025, its largest moves.
  • ClearPoint Neuro's Accumulated Depreciation & Amortization stood at $159000.0 in 2021, then jumped by 53.46% to $244000.0 in 2022, then declined by 18.03% to $200000.0 in 2023, then changed by 0.0% to $200000.0 in 2024, then surged by 758.5% to $1.7 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $1.7 million, $200000.0, and $200000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 ClearPoint Neuro 375.84 Mn 340.24 Mn 7.76 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 1.72 Mn
Dec 31, 2025 1.72 Mn
Dec 31, 2024 200,000.00
Dec 31, 2024 200,000.00
Dec 31, 2023 200,000.00
Dec 31, 2023 200,000.00
Dec 31, 2022 244,000.00
Dec 31, 2022 244,000.00
Dec 31, 2021 159,000.00
Dec 31, 2021 159,000.00
Dec 31, 2020 334,000.00
Dec 31, 2020 334,000.00
Dec 31, 2019 100,000.00
Dec 31, 2019 100,000.00
Dec 31, 2018 109,439.00
Dec 31, 2018 109,439.00
Dec 31, 2017 116,454.00
Dec 31, 2017 116,454.00
Dec 31, 2016 155,707.00
Dec 31, 2016 155,707.00
Dec 31, 2015 211,946.00
Dec 31, 2015 211,946.00
Dec 31, 2014 343,929.00
Dec 31, 2014 343,929.00
Dec 31, 2013 400,516.00
Dec 31, 2013 400,516.00
Dec 31, 2012 398,970.00
Dec 31, 2012 398,970.00
Sep 30, 2012 1.10 Mn
Sep 30, 2012 1.10 Mn
Jun 30, 2012 1.00 Mn
Jun 30, 2012 1.00 Mn
Dec 31, 2011 336,885.00
Dec 31, 2011 336,885.00